NCT04508582

Cardiac and Immune Cell Function in Preeclampsia

Completed Last updated 10 March 2025

What this trial tests

trial testing Cardiovascular magnetic resonance in Preeclampsia in 86 participants. Completed in 6 March 2024.

Timeline

7 January 2020

Primary endpoint
6 March 2024

6 March 2024

Quick facts

Lead sponsor	Queen Mary University of London
Status	Completed
Study type	OBSERVATIONAL
Enrollment	86
Start date	7 January 2020
Primary completion	6 March 2024
Estimated completion	6 March 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

• Cardiovascular magnetic resonance
• Echocardiography
• Blood test — full drug profile →

Conditions studied

• Preeclampsia — all drugs for Preeclampsia →
• Hypertension — all drugs for Hypertension →
• Pregnancy Induced Hypertension — all drugs for Pregnancy Induced Hypertension →
• Pregnancy Related — all drugs for Pregnancy Related →

Sponsor

Queen Mary University of London

Who can join

18 and older, female only, with Preeclampsia or Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Preeclampsia is a multi-system vascular disease which affects 2-5% of pregnancies. It is also a risk factor for the development of cardiovascular disease later in life and a number of functional and structural cardiac changes have been found in this population of patients.

In mouse models disruption of a group of immune cells, neutrophils, has led to alteration of the placenta and offspring consistent with those seen in preeclampsia. These mice also have an abnormal cardiac function and structure (Nadkarni et al 2016). The investigators hypothesis that this may also occur in humans.

This study aims to intimately link the maternal immunological and vascular components of cardiac dysfunction in women preeclampsia. The investigators hypothesise that in preeclampsia activated neutrophils may affect maternal immune system thus leading to myocardial injury and altered cardiac function. The study intends to identify the mechanisms by which the maternal immune system (focusing on neutrophil and T-cell subsets) affects cardiac function in women with preeclampsia. Specific aims to be addressed are:

Aim 1: To correlate specific neutrophil phenotype(s) and function to cardiac function in women with preeclampsia during pregnancy

Aim 2: To test whether specific activated neutrophil phenotype persists postpartum and whether this neutrophil phenotype correlates with cardiac function in women with preeclampsia postpartum

The study population will comprise of 3 groups:

1. Normotensive pregnant (\~33 patients)
2. Pregnancy-induced hypertension (PIH; New-onset hypertension after 20 weeks without proteinuria; \~33 patients)
3. Preeclampsia (\~34 patients)

Cardiac function will be evaluated using cardiovascular magnetic resonance, echocardiography and cardiac markers in the blood. The participants immune system will be assessed from blood samples looking at the immune cells, hormone levels and inflammatory and non-inflammatory mediators.

The secondary research objective is to investigate whether changes in the immune system and cardiac function in participants is persistent after delivery. Therefore participants will have scans and blood tests both antenatally and at 3 months postnatally.

By identifying key changes in immune cell type and function with cardiac abnormalities in women with preeclampsia, data obtained from this study could provide novel insight into how the maternal immune system influences cardiac changes in normal and preeclamptic pregnancies. Identifying such links could pave the way for future therapeutic targets.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.